FY26 Full-Year Volume Growth: 3-4%
Despite H1 FY26 degrowth of -5% YoY, management expects Q4 recovery to drive full-year volume growth of 3-4%, with strong domestic momentum continuing into Q4.
NOCIL / guidance tracker
Keep management guidance in view.
NOCIL · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
FY27 Double-Digit Volume Growth
MD expects overall double-digit volume growth in FY27, driven by US tariff recovery (50% of lost volumes expected back within 2-3 months), India-EU FTA tailwinds, and new product ramp-up.
New TDQ Capacity: H1 CY26 Production Trials
TDQ antioxidant expansion at Dahej is ahead of original schedule, with production trials planned H1 CY26. Customer approvals expected during FY27 with volume ramp-up through FY28.
Annual Margin Improvement: 150 bps over 2-3 Years
Management targets at least 150bps annual EBITDA margin improvement through operational efficiency initiatives, new product mix, and improved capacity utilization, over the next 2-3-4 years.
Double-digit volume growth in FY27
Management targets double-digit volume growth for the coming year, building on Q4 momentum and new capacities.
EBITDA margin improvement of 150 bps from FY26 base
Management expects to improve EBITDA margin by 150 basis points from FY26 levels through cost efficiencies and operating leverage.
₹130 crore specialty capex completion by H1 FY28
New integrated specialty facility will be commissioned by H1 FY28, targeting 20% specialty mix.
Anti-dumping duty approval expected by mid-June 2026
Central government is expected to approve DGTR's anti-dumping duty recommendations within 90 days, i.e., by mid-June.